CECLOR CD
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Jun 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CECLOR CD is an extended-release oral tablet formulation approved by the FDA in 1996 as an NDA small-molecule drug. The generic name and specific indications are not currently available in the provided data. It is a small-molecule therapeutic indicated for oral administration.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), expect team contraction and transition focus toward lifecycle management or product transition roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, CECLOR CD offers limited career advancement opportunities. This product is in mature/decline phase, making it suitable only for cost-management or transition roles rather than growth-oriented positions.
Brand ManagerField Sales Representative
Worked on CECLOR CD at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.